As Australia’s largest manufacturer of sterilants, disinfectants and professional cleaning technologies, Whiteley have been protecting lives and livelihoods since 1933.
As Australia’s largest manufacturer of sterilants, disinfectants and healthcare cleaning technologies, Whiteley have been protecting lives and livelihoods since 1933.
Whiteley is a TGA licensed manufacturer of therapeutic goods and on the campus in Tomago in the Hunter Region of New South Wales, they manufacture innovative products that enable cleaning and disinfection that meet international standards. Whiteley provide quality products in the fields of Endoscopy, Surgical and Theatre, Hospital Infection Prevention, Central sterilisation departments, Aged care, Contract cleaning and Professional cleaning services.
Whiteley remains an Australian family-owned business led by Dr Greg Whiteley, a world renowned expert on Infection Prevention and Control. The Business operates throughout Asia Pacific and exports to over 20 international markets including across Southeast Asia, China and the US.
At Whiteley there is a obsessive focus on clinical research to drive constant innovation in the vital area of Infection Prevention. Their commitment to research programs in emerging fields such as bacterial biofilms are driving world first technologies in this area, including Surfex® which holds the title of the world’s first dry surface biofilm remover. Several Whiteley publications are recognised as seminal papers in field, particularly with Dry Surface Biofilms.
Whilst the height of the SARS-CoV-2 (COVID-19) pandemic may be behind us, Superbugs do and will continue to take lives. This will remain a core focus for Whiteley and they continue to focus on the development of appropriate hygiene interventions. Whiteley are researching how superbugs bind onto surfaces, and the transfer mechanisms that lead to others becoming infected. Understanding how to stop these biofilms forming and contributing to patient infections has the potential to save thousands of lives. The intent is not to replace antibiotics, but to provide additional processes and defences in the prevention or treatment of infections. In recognition of his groundbreaking work, Dr Greg Whiteley was recently appointed as an Adjunct Associate Professor in the Faculty of Medicine and Health at the University of Sydney.
From beginnings during the Great Depression, to a global fight against Pandemics and Superbugs the future looks bright for Whiteley. With new products, new claims, new research, new facilities and many new product opportunities being investigated they look forward to delivering even more leading cleaning and disinfection technology to the market in the future.
Dr Greg Whiteley added “whilst there is still the ability to protect lives and livelihoods we will be continuing to fulfill our company mission of protecting lives and livelihoods.’’
Whiteley believes patient safety should be protected by technology that reduces the risks of healthcare associated infections. Whiteley is committed to developing cutting edge technologies and to create safer, cleaner healthcare environments.
We live by 6 core values as we fulfil our mission.
Inspire our people to be the best they can, and embrace their passion
Create market leading solutions which sustain, enhance, and disrupt
Take the extra step to get the very best results
Work effectively as one team to achieve our goals
Put the customer at the heart of everything we do
Get results the right way, being honest, clear and respectful
To deliver the best we employ the best. At Whiteley, you will find a broad cross-functional team who are all experts in their respective professional fields.
Our team work together to deliver the goals of the business and to meet the needs of our broad base of customers across numerous channels. Everyone at Whiteley is driven by a shared passion to protect lives and livelihoods.
At Whiteley, we have a team of dedicated scientists under the leadership of Dr Greg Whiteley. Their focus is on clinical research to drive innovation in the area of Infection Prevention, sterilants, and hygiene. Turning ground-breaking discoveries into commercial products requires the focused work of our Development Scientists, our Medical and Regulatory team and our Production and Quality Assurance teams.
Getting our products to market through our extensive network of distributors is led by our Sales and Marketing teams. With Whiteley, professional sales teams focused on Infection Prevention, Medical Device Reprocessing, and professional cleaning we have the needs of our customers firmly in focus.
Our marketing team ensure that our brands fully meet the needs of our customer base. They ensure that our brands are well known, easy to use and that the training and education needs of our diverse customer base are met.
Our production team produce most of our products at the Whiteley Campus in Tomago, in the Hunter Region of New South Wales. Here our team is comprised of manufacturers, packaging technologists, warehousing, and dispatch personnel. They are complemented by our friendly Customer Service team who help to maintain the Whiteley reputation of exceptional service and support.
And behind all of this, you will find the other heroes of our organisation including our finance and accounts team, procurement specialists and factory engineers who all look to the future and help deliver effective business operations.
Please get in touch with us and let our exceptional team help your business or facility to deliver exceptional quality outcomes.
Executive Chairman
Non Executive Director
Non Executive Director
Non Executive chairman
Managing Director
Our head office is located in North Sydney.
The Whiteley Manufacturing campus is in Tomago, in the Hunter Region of New South Wales.
Suite 501, Level 5
12 Mount Street
North Sydney
NSW 2060 Australia
19-23 Laverick Avenue
Tomago, Newcastle
NSW 2322 Australia
3-5 Kahu Street
Otahuhu 1640
Auckland
New Zealand
Whiteley manufactures products that comply with Australian and International environmental policy.
The Whiteley manufacturing facility has the following accreditations:
Whiteley offers advice, training and practical support for all of your infection prevention, medical device reprocessing, and professional cleaning needs.
You can view our product safety data sheets, technical bulletins and find out about the products from our range.
Speaker: Doctor Arthika Manoharan
Qualifications: Postdoctoral Research Fellow at University of Sydney
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at The University of Sydney Infectious Diseases Institute, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Professor Slade Jensen
Qualifications: B.Med.Sc. (USyd) PhD. (USyd). FASM
Speaker Profile:
Slade is a Professor of Microbiology and Infectious Diseases in the School of Medicine, Western Sydney University and Research Director of the Antibiotic Resistance and Mobile Elements Group, and the Limb Preservation and Wound Research Group, both of which are based at the Ingham Institute for Applied Medical Research. He obtained a Ph.D. from the University of Sydney focused on the role of horizontal gene transfer in bacterial evolution. His current research interests include the development of novel antimicrobials, the evolution of antibiotic resistance in hospital pathogens, such as ‘Golden Staph’, and the role of host-microbe interactions in disease progression, particularly in the context of diabetes-related foot ulcers.
Topic: Microbes, biofilms and diabetes-related foot ulcers
Presentation Outline: Slade will discuss how his team’s research has assisted in changing the understanding of the pathology of chronic ulceration in diabetic foot infections, from that of infection with planktonic bacteria to that of infection with biofilm. Due to the resistance of biofilms to antimicrobial penetration, increased emphasis is now given to removal of adequate volumes of tissue with debridement and the use of anti-biofilm compounds.
Speaker: Professor Kate Moore
Qualifications: MB BS Syd, MD Liv, FRCOG, FRANZCOG, CU
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at the University of Sydney, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Associate Professor Greg Whiteley
Qualifications: FEHA, MASM, MSHEA, PhD, M Safety Sc, B App, Dip AICD
Speaker Profile:
Dr Greg Whiteley is an Adjunct Associate Professor in the Faculty of Medicine and Health at the University of Sydney, a Fellow in the School of Medicine at Western Sydney University and is also the Executive Chairman of Whiteley Corporation. Assoc. Prof Whiteley’s qualifications include a Bachelor of Applied Science (Hawkesbury Agricultural College), a Master of Safety Science (University of New South Wales), a Diploma from the Australian Institute of Company Directors (University of New England) and a PhD (Western Sydney University).
Dr Whiteley is a Life Fellow of Environmental Health Australia, a Member of the Society of Healthcare Epidemiology of America and is a Member of the Australian Society of Microbiology. He currently serves as a director of the trade association known as ACCORD Australia, and also as an expert consultant to the Infection Control Committee for the Australian Dental Association. He has previously served on HE-023 with Standards Australia.
His on-going research interests focus on biofilms found within healthcare settings, healthcare hygiene and the cleanliness of medical devices. Findings from this research team include publications outlining the extent of biofilm problems within healthcare and other settings, monitoring solutions including ATP testing, and extensive findings on the cleaning and disinfecting implications from biofilms on healthcare surfaces and reusable medical devices.
Dr Whiteley has previously been an Industry Partner for an ARC Grant in conjunction with Macquarie University, a Collaboration Partner Study Director for an iMCRC Grant with the School of Medicine at Sydney University, the Study Director of a CRC-P Grant investigating novel diagnostic and treatment options for wound care co-jointly partnering with AMP Control and the University of Newcastle and Western Sydney University.
Dr Whiteley is currently the Executive Chairman of Whiteley Corporation. He bears ultimate responsibility under Commonwealth Legislation for the Therapeutic Goods registrations and the manufacturing license of the manufacturing location in Tomago. Dr Whiteley has additionally co-authored many patents and peer reviewed publications.
Topic: Advances in Biofilm TestingÂ
Presentation Outline: This topic will provide an overview into key lessons and research findings on dry surface and wet surface biofilms and their impact on critical healthcare departments. Published research on the presence of biofilms containing viable multi-resistant organisms and the critical role of rigorous cleaning processes to prevent hospital acquired infections (HAI’s). Understanding why cleaning protocols must adapt to account for our new logic of the role of biofilms in bacterial survival and transmission of infections.